Pharma Stock Soars Through Volatility for Nice Profits
Volatility is back, but the “V-word” isn’t all bad—traders just need the right strategy to leverage the market churn.
Yesterday, stocks posted a sharp recovery from the last week’s doldrums, gaining back much of the ground they lost so dramatically. The rally appears to be continuing today.
At the end of the past week of high volatility trading, markets are close to even from where they were one month ago. Blue chip stocks like Home Depot and Apple have been at the forefront of the rally.
Today’s Top Performer comes from the pharmaceutical sector, which continues to be a strong source of short-term gains even as market conditions evolve.
This morning, TBPH announced a new research agreement, designed to facilitate global collaboration with Janssen. Together, the two companies will focus on the further development of TD-1473, a potential treatment for intestinal inflammation disorders.
TBPH will receive up to $1 billion potential payments in the deal, with $100 million received upfront. TD-1473 is garnering significant interest as a potential treatment for conditions with few current options, including ulcerative colitis and Crohn’s disease.
Investors bought the stock on heavy volume on the news, driving it to gains closing in on 15% at the time of this writing. Recent volatility doesn’t change the fundamental fact about current equity valuations: investors are hungry for hidden growth potential. And few sectors can deliver sudden shifts in growth potential like pharma.
Diverse Plays, Great Profits: All in a single news day.
Keep checking our Top Performer blog each trading day: we analyze a wide variety of news events to find profitable stock trades for many different trading strategies. Or, if you’d prefer these updates delivered to your inbox, sign up for our free “Movers and Shakers” newsletter.
Our blog homepage will help you get a sense for just how many smart strategies a real-time news analytics platform can unlock. From short selling to momentum trading, from geopolitics to blockchain, News Quantified provides a powerful tool for leveraging the strategy you’ve selected with the sort of data typically only accessible to big institutional investors. Regular readers of our blog know that there’s virtually no limit to the number of news events that News Quantified can translate into real stock trading profits.
If you’re ready to move beyond the blog and learn more about our platform, click the button below to sign up for a free training seminar today. We’ll show you around the platform and suggest some strategies that many of our users are taking advantage of to find consistent news-based trading profits.